We are located in Paris
At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from rare diseases.
Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side.
-
Unified data umbrella: Seamlessly generate insights from over 25+ sources, including clinical trials, publications, omics datasets, patents, anonymized patient datasets (proprietary) and other specialized databases (internal and external).
-
Navigating the Disease Landscape: Generate comprehensive network models that visualize disease progression and drug interactions at the molecular level.
-
Exploring Hidden Connections: Find correspondence between networks to to identify promising drug-disease matches that might have been missed.
-
Expansion of Treatment Options: Uncover novel uses for existing medications based on their interaction with disease pathways and pharmacological actions.
-
Accelerate Drug Development: Pinpoint promising drug leads with high potential for further development.
-
Optimize Clinical Trials: Clinical endpoint mapping and adverse events mapping facilitates identification of potential biomarkers that can streamline drug development by analyzing previous treatment response in patients.
Introducing Our Fully-Integrated Drug Discovery Framework
NEXUS-Rx
How NEXUS-Rx works?
Accelerate drug discovery by illuminating complex disease landscapes and uncovering hidden therapeutic opportunities within vast data types
OUR CLIENT PORTFOLIO
"My research team is primarily focused on the physiology of body weight homeostasis and food intake. A strong component of our work encompass physiological approaches of brain circuits dictating metabolic control. With the emergence of omics technology it has become crucial to benefit from an expertise in bio informatics. My encounter with MedInsights was a revelation in that regards because the company not only has cutting edge knowledge and tools but also-which is quite unique in my experience-is offering mentoring and training support for post-doc and fellows to develop an understanding of the pipeline of analysis and procedure to be followed. MedInsights has been giving talks in my lab on several occasion and we are now actively seeking to make MedInsights part of of all our developing projects in which their expertise and knowledge has become a crucial determinant of competitivity in academic publication, data analysis and fund raising."
Prof. Serge Luquet
Université Paris Cité BFA UMR CNRS 8251
MEMBERSHIPS
MedInsights is a part of REPO4EU , Future4care and Paris Biotech Santé
